Primäre arterielle Hypertonie: Update 2012

Schlüsselwörter

arterielle Hypertonie - renale sympathische Denervation - Kombinationstherapie

Keywords

primary hypertension - renal sympathetic denervation - antihypertensive combination therapy

• Literatur

• 1 Burgaz A, Orsini N, Larsson SC et al. Blood 25-hydroxyvitamin D concentration and hypertension. J Hypertens 2011; 29: 636-645
• 2 Forman JP, Choi H, Curhan GC. Fructose and vitamin C intake do not influence risk for developing hypertension. J Am Soc Nephrol 2009; 20: 863-871
• 3 Ha V, Sievenpiper JL, de Souza RJ et al. Effect of fructose on blood pressure. Hypertension 2012; 59: 787-795
• 4 Haller H, Ito S, Izzo JL et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
• 5 Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; [Epub ahead of print]
• 6 Hermida RC, Ayla DE, Mojon A et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-2321
• 7 Hermida RC, Ayla DE, Mojon A et al. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol Int 2010; 27: 1629-1651
• 8 Hermida RC, Ayla DE, Mojon A et al. Influence of time of day of blood-pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011; 34: 1270-1276
• 9 Houston TK, Allison JJ, Sussman M et al. Culturally appropriate storytelling to improve blood pressure. Ann Intern Med 2011; 154: 77-84
• 10 Jalal DI, Smits G, Johnson RJ et al. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 2010; 21: 1543-1549
• 11 Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; [Epub ahead of print]
• 12 Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension. Lancet 2009; 373: 1275-1281
• 13 Mahfoud F, Vonend O, Bruck H et al. Interventionelle renale Sympathikusdenervation zur Behandlung der thrapierefraktären Hypertonie. Dtsch Med Wochenschr 2011; 136: 2418-2424
• 14 Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 16: 547-553
• 15 Parving HH, Brenner BM, McMurray JJV et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; Feb 14. [Epub ahead of print]
• 16 Schmieder RE, Redon J, Grassi G et al. ESH Position Paper: Renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841
• 17 Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure. Br Med J 2011; 343: d4366
• 18 Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
• 19 Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial). Lancet 2010; 376: 1903-1909
• 20 The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585
• 21 Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565
• 22 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559